JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive: IFN-alpha (3 MU/every 10 days) was therefore re-introduced in association with Imatinib (400 mg/die) and ASA, obtaining a good control of the disease with deep molecular response (DMR) of CML, but JAK2 still positive at a constant allelic burden (20%) at 7 years from CML diagnosis.